This Cheap Biotech Offers Investors a Play on ALS If Trial Data Continues to Impress
This Cheap Biotech Offers Investors a Play on ALS If Trial Data Continues to Impress
如果臨床試驗數據繼續令人印象深刻，這家廉價的生物科技公司將爲投資者提供一個關於肌萎縮性側索硬化症的投資機會。
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登入免費觀看全文
登入/註冊